Combination of phosphodiesterase-5 inhibitors and α-blockers in patients with benign prostatic hyperplasia: Treatments of lower urinary tract symptoms, erectile dysfunction, or both?

BJU International

Volumn 97, Issue SUPPL. 2, 2006, Pages 39-43

  Carson, Culley C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

1 blockers; Alfuzosin; BPH; Erectile dysfunction; LUTS; PDE 5 inhibitors; Treatment

Indexed keywords

ACEBUTOLOL; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; DOXAZOSIN; DUTASTERIDE; ENALAPRIL; FINASTERIDE; NITRIC OXIDE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN;

BLADDER FUNCTION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CORPUS CAVERNOSUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; ISOLATED ORGAN; LIBIDO DISORDER; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REFLEX; REVIEW; RISK FACTOR; SIDE EFFECT; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE TONE; SYMPATHETIC TONE; URETHRA DISEASE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; DRUG THERAPY; DRUG THERAPY, COMBINATION; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; URINATION DISORDERS;

EID: 33644824661     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06105.x     Document Type: Review

References (21)

1. Rosen R Altwein J Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 2003 44 637 49
2. Rohrmann S Smit E Giovannucci E Platz EA Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey Am J Epidemiol 2004 159 390 7
3. Joseph MA Harlow SD Wei JT et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men Am J Epidemiol 2003 157 906 14
4. Roberts RO Jacobsen SJ Rhodes T et al. Cigarette smoking and prostatism: a biphasic association? Urology 1994 43 797 801
5. Braun M Wassmer G Klotz T Reifenrath B Mathers M Engelmann U Epidemiology of erectile dysfunction: results of the 'Cologne male survey' Int J Impot Res 2000 12 305 11
6. Lam JS Cooper KL Kaplan SA Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia Med Clin North Am 2004 88 281 308
7. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations J Urol 2003 170 530 47
8. Naderi N Mochtar CA de la Rosette JJ Real life practice in the management of benign prostatic hyperplasia Curr Opin Urol 2004 14 41 4
9. Palea S Barras M Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum BJU Int 2003 91 873 7
10. Mayoux E Ramirez JF Pouyet T Barras M Arbilla S Galzin AM Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats Eur Urol 2004 45 110 6
11. Grimm RH Grandits GA Prineas RJ et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) Hypertension 1997 29 8 14
12. Kirby RS O'Leary MP Carson C Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction BJU Int 2005 95 103 9
13. van Moorselaar RJ Hartung R Emberton M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction BJU Int 2005 95 603 8
14. Elhilali M Emberton M Matzkin H et al. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice BJU Int 2006 97 513 9
15. Sairam K Kulinskaya E McNicholas TA Boustead GB Hanbury DC Sildenafil influences lower urinary tract symptoms BJU Int 2002 90 836 9
16. McVary K Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology BJU Int 2006 97 Suppl. 2 23 8
17. Yassin A Diede HE Combination therapy. Alpha1-adrenoreceptor blockade and tadalafil in BPH population Int J Impot Res 2003 15 Suppl. 6 PS 2-5
18. Kloner RA Jackson G Emmick JT et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men J Urol 2004 172 1935 40
19. Giuliano F Kaplan S Fournié P et al. Tadalafil shows no clinically haemodynamic interaction with alfuzosin Eur Urol 2005 3 Suppl. 137 A537
20. Kaplan SA Reis RB Kohn IJ Shabsigh R Te AE Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction Urology 1998 52 739 43
21. Kaplan SA Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function Urology 2004 63 428 34